Security key
87184Q206
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS)
CUSIP: 87184Q206
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 462,954
- Total 13F value
- $12,375
- Share change
- -4,753,843
- SEC-reported price per share
- $0.03
- Number of holders
- 4
- Value change
- -$1,107,011
- Number of buys
- 2
- Number of sells
- 39
- Shares outstanding
- 27,196,692
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
4
Top holders
4
SYRS full security history
Ownership snapshot
Full 13F holder table
Syros Pharmaceuticals, Inc. SEC filings
Syros Pharmaceuticals, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Avidity Partners Manageme...
Disclosed value leader
Invus Global Management, LLC
Comparable rows
15/15
Latest evidence
31 Dec 2024
13D/G
13F
Lead comparable stake: 7.6%
13D/G row: Avidity Partners Management LP
Showing 1-6 of 15 holder rows.
Quick read
Avidity Partners Management LP leads the comparable SEC ownership view at 7.6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Avidity Partners Management LP's linked filing trail.
Comparable ownership
Top 5
Avidity Partners Management LP
7.6%
Invus Global Management, LLC
3.8%
Samsara BioCapital, L.P.
2.6%
ADAGE CAPITAL PARTNERS GP, L.L.C.
2%
Point72 Asset Management, L.P.
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Avidity Partners Management LP |
13D/G
|
7.6%
|
$61,441
2,048,020 shares
|
$0 | 31 Dec 2024 |
| Invus Global Management, LLC |
13D/G
Invus Public Equities, L.P.
|
3.8%
|
$776,595
1,063,829 shares
|
$0 | 31 Dec 2024 |
| Samsara BioCapital, L.P. |
13D/G
|
2.6%
|
$21,213
707,114 shares
|
$0 | 18 Nov 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13D/G
Adage Capital Management, L.P.
|
2%
|
$15,957
531,914 shares
|
$0 | 31 Dec 2024 |
| Point72 Asset Management, L.P. |
13D/G
|
0%
|
$14.88
496 shares
|
$0 | 31 Dec 2024 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
10%
|
$631,985
2,750,151 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
4
Shares
462,954
Rows available
4
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
4
Q1 2025 holders
4
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|